Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1

Conditions

Pleural Effusion, Malignant 4Breast Neoplasms 4Immunoglobulin Light-chain Amyloidosis 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Exanthema 2Amyloidosis 2Waldenstrom Macroglobulinemia 1Urologic Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Tissue Adhesions 1Skin Toxicity 1Sezary Syndrome 1Ras-wildtype Colorectal Cancer 1Polyps 1Polycystic Ovary Syndrome 1Pain 1Ovarian Neoplasms 1Neurofibromatosis 2 1Neoplasms, Second Primary 1Neoplasms 1Myoma 1Menstruation Disturbances 1Melanoma 1

Interventions

Gels 2Fulvestrant 2Doxycycline 2Dapsone 2ruxolitinib 1dexpanthenol 1ceterizine hydrochloride 1capivasertib 1benralizumab 1Triamcinolone Acetonide 1Tetracycline 1Sirolimus 1Provitamins 1Prednisone 1Panitumumab 1Minocycline 1Loperamide 1Irinotecan 1IFL protocol 1Hydrocortisone 1Erlotinib Hydrochloride 1Clindamycin 1Cetuximab 1Anti-Bacterial Agents 1Alpelisib 1Acitretin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Exanthema × Doxycycline × Clear all
NCT02239731 2018-02-27

Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients

Vyne Therapeutics Inc.

Phase 2 Completed
24 enrolled

Exanthema

NCT00803842 2015-02-26

Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash

Northwestern University

Phase NA Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡